SCOPUS 정보 검색 플랫폼

AIDS

Volumn 24, Issue 17, 2010, Pages 2757-

Raltegravir-induced cerebellar ataxia

(4) Reiss, Kim A a Bailey, Justin R b Pham, Paul A b Gallant, Joel E b

a Department of Medicine ^* (United States)

b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; FLUTICASONE; RALTEGRAVIR; TENOFOVIR;

ADULT; ATAXIA; CASE REPORT; CEREBELLAR ATAXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMETRIA; FEMALE; FOOT TREMOR; HAND TREMOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; PATIENT ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREMOR;

CEREBELLAR ATAXIA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 78349290795 PISSN: 02699370 EISSN: 14735571 Source Type: Journal
DOI: 10.1097/QAD.0b013e32833fca42 Document Type: Letter

Times cited : (11)

References (5)

1
- 52449097240
- Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
- Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51:5843-5855.
- (2008) J Med Chem , vol.51 , pp. 5843-5855
- Summa, V.¹ Petrocchi, A.² Bonelli, F.³ Crescenzi, B.⁴ Donghi, M.⁵ Ferrara, M.⁶

2
- 34147136222
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial
- Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
- (2007) Lancet , vol.369 , pp. 1261-1269
- Grinsztejn, B.¹ Nguyen, B.Y.² Katlama, C.³ Gatell, J.M.⁴ Lazzarin, A.⁵ Vittecoq, D.⁶

3
- 47949120697
- Raltegravir with optimized background therapy for resistant HIV-1 infection
- Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
- (2008) N Engl J Med , vol.359 , pp. 339-354
- Steigbigel, R.T.¹ Cooper, D.A.² Kumar, P.N.³ Eron, J.E.⁴ Schechter, M.⁵ Markowitz, M.⁶

4
- 77955049938
- Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution
- Masia M, Enriquez R, Sirvent A, Gutierrez F. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 2010; 61:189-190.
- (2010) J Infect , vol.61 , pp. 189-190
- Masia, M.¹ Enriquez, R.² Sirvent, A.³ Gutierrez, F.⁴

5
- 78049454722
- Merck&co Inc. Whitehouse Station, New Jersey, USA
- Isentress (package insert); Merck&co Inc., Whitehouse Station, New Jersey, USA; 2010
- (2010) Isentress (Package Insert)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.